Investors Back Immuneel’s Vision for Affordable Advanced Cancer Therapies
Bengaluru, India: Cell and gene therapy company Immuneel Therapeutics has raised more than ₹100 crore (approximately $10.5 million) in fresh funding from investors including Singularity AMC, Rainmatter, and other strategic partners, strengthening its efforts to expand access to advanced cancer therapies in India and international markets.
The new investment will support the expansion of manufacturing capabilities, improve patient access to the company’s CAR-T cell therapy Qartemi (varnimcabtagene autoleucel), accelerate innovation in cell and gene therapy platforms, and advance global commercialization opportunities.
Founded with a mission to transform cancer treatment through next-generation cell and gene therapies, Immuneel has emerged as one of India’s leading companies in the advanced therapeutics space. The company has focused on building integrated scientific, clinical, and manufacturing capabilities to develop and deliver complex cellular therapies within the country.
The funding comes at a time when India’s cell and gene therapy ecosystem is gaining momentum, supported by increasing clinical adoption, improving manufacturing infrastructure, and growing investor interest in advanced biologics and precision medicine.
According to the company, the latest investment reflects growing confidence in India’s ability to become a global hub for the development and manufacturing of advanced therapies.
A key focus area for Immuneel will be expanding access to Qartemi, its CAR-T cell therapy developed for the treatment of certain blood cancers. CAR-T therapies involve engineering a patient’s own immune cells to recognize and attack cancer cells and represent one of the most significant advances in cancer treatment over the past decade.
The company stated that the new funding will help strengthen its manufacturing footprint, support continued research and development efforts, and enable broader patient access to innovative therapies that have traditionally remained out of reach for many patients due to cost and availability constraints.
The investment also highlights increasing investor confidence in India’s emerging cell and gene therapy sector, which is expected to play an important role in the future of oncology and personalized medicine.
As Immuneel continues to scale its operations, the company remains focused on its core mission of making transformative cell and gene therapies more accessible and affordable for cancer patients while advancing India’s position in the global advanced therapeutics landscape.
Garlic Compound Improves Muscle Function in Aging Mice Through Fat-Brain Signaling
